 | Up a level |
Journal Article
Bergmark, Brian A., O'Donoghue, Michelle L., Murphy, Sabina A., Kuder, Julia F., Ezhov, Marat V., Ceska, Richard, Gouni-Berthold, Ioanna, Jensen, Henrik K., Tokgozoglu, S. Lale, Mach, Francois, Huber, Kurt, Gaciong, Zbigniew, Lewis, Basil S., Schiele, Francois, Jukema, J. Wouter, Pedersen, Terje R., Giugliano, Robert P. and Sabatine, Marc S. (2020). An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiol., 5 (6). S. 709 - 714. CHICAGO: AMER MEDICAL ASSOC. ISSN 2380-6591
Giugliano, Robert P., Pedersen, Terje R., Park, Jeong-Gun, De Ferrari, Gaetano M., Gaciong, Zbigniew A., Ceska, Richard, Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose 
ORCID: 0000-0002-8844-0718, Schiele, Francois, Mach, Francois, Ott, Brian R., Kanevsky, Estelle, Pineda, Armando Lira, Somaratne, Ransi, Wasserman, Scott M., Keech, Anthony C., Sever, Peter S. and Sabatine, Marc S.
(2017).
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Lancet, 390 (10106).
S. 1962 - 1972.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X
O'Donoghue, Michelle L., Fazio, Sergio, Giugliano, Robert P., Stroes, Erik S. G., Kanevsky, Estella, Gouni-Berthold, Ioanna, Im, KyungAh, Pineda, Armando Lira, Wasserman, Scott M., Ceska, Richard, Ezhov, Marat V., Jukema, J. Wouter, Jensen, Henrik K., Tokgozoglu, S. Lale, Mach, Francois, Huber, Kurt, Sever, Peter S., Keech, Anthony C., Pedersen, Terje R. and Sabatine, Marc S. (2019). Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial. Circulation, 139 (12). S. 1483 - 1493. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1524-4539